Hypoxia-Activated Prodrug TH-302 Targets Hypoxic Bone Marrow Niches in Preclinical Leukemia Models.

导出 OA

翻译打印收藏纠错

第一作者： Juliana,Benito

第一单位： Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas.

作者： Juliana,Benito ^[1] ; Marc S,Ramirez ^[2] ; Niki Zacharias,Millward ^[3] ; Juliana,Velez ^[1] ; Karine G,Harutyunyan ^[1] ; Hongbo,Lu ^[1] ; Yue-Xi,Shi ^[1] ; Polina,Matre ^[1] ; Rodrigo,Jacamo ^[1] ; Helen,Ma ^[1] ; Sergej,Konoplev ^[4] ; Teresa,McQueen ^[1] ; Andrei,Volgin ^[5] ; Marina,Protopopova ^[6] ; Hong,Mu ^[1] ; Jaehyuk,Lee ^[2] ; Pratip K,Bhattacharya ^[7] ; Joseph R,Marszalek ^[6] ; R Eric,Davis ^[8] ; James A,Bankson ^[2] ; Jorge E,Cortes ^[1] ; Charles P,Hart ^[9] ; Michael,Andreeff ^[1] ; Marina,Konopleva ^[10]

作者单位： Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[1] Imaging Physics, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[2] Department of Experimental Diagnostic Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[3] Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[4] Department of Bioinformatics and Computational Biology, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[5] Institute for Applied Cancer Science, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[6] Cancer Systems Imaging, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[7] Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, Texas. ^[8] Threshold Pharmaceuticals, Inc., South San Francisco, California. ^[9] Department of Leukemia, University of Texas MD Anderson Cancer Center, Houston, Texas. mkonople@mdanderson.org. ^[10]